Martin Griesshammer, MD, PhD, Johannes Wesling University Clinic, discusses past and current efforts to improve treatment options for patients with polycythemia vera.
Real-world studies are crucial in understanding how best to optimize treatment options for patients with polycythemia vera (PV), says Martin Griesshammer, MD, PhD, professor and medical director of the Department of Haematology, Haemostaseology, Oncology, and Palliative Care, at Johannes Wesling University Clinic.
Transcript
What can be done to optimize the treatment of PV in elderly patients or those with comorbidities?
Elderly patients with PV have special interests because we know that the rate of cardiovascular and cerebrovascular events is elevated in PV. And this is especially true for elderly patients because they have a higher risk for getting cerebral and cardiovascular problems. We should make a common effort together with a cardiologist and an angiologist to establish the best treatment for these elderly patients.
What research efforts are currently underway to address the unmet needs in PV treatment?
What we do at the moment is, of course, trials about the real world. And there has been very interesting analysis of Francesca Palandri [Francesca Palandri, MD, PhD, Institute of Hematology "L. and A. Seràgnoli", Sant'Orsola-Malpighi University Hospital, Bologna, Italy] focusing on the real-world problem. So that means, for example, what are we going to do with patients that are resistant or intolerant to hydroxyurea? Are they really switched to ruxolitinib? This is not the case. Only 30% of the patients having resistance to hydroxyurea are really switched to ruxolitinib, [and] that should be 100%. All these efforts and studies and analysis in the real-world setting will help to improve in the future therapy for our PV patients.
There's been more research into the use of ruxolitinib for the treatment of PV, including a study you worked on that compared the drug to standard therapy and a study being presented at EHA 2023 evaluating it as a second-line therapy. What other research is needed to convince providers and federal agencies to get behind the use of this drug for patients with PV?
Ruxolitinib has been established and licensed for PV since 2014, in Germany and Europe. We now have nearly a 10-year experience. It's a very reliable drug with very few side effects; it is very effective over many years, and it really helps patients with PV. It is necessary to carry on with these results and have other real-world analysis to reassure us that it is an excellent second-line therapy.
Specialty Pharmacists at the Forefront: Elevating Care for Rare Diseases
May 1st 2024In the US, a disease is considered rare when it affects fewer than 200,000 persons, or 1 in every 1500 individuals, with an estimated total of 25 to 30 million Americans overall living with a rare disease at any given time.
Read More
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Latest Advances and Updates of Treatment in the Real World at AUA
May 1st 2024The annual meeting of the American Urological Association (AUA) not only presents the newest therapies coming out but showcases the latest in how treatments are being used in the real world, said Stephen Freedland, MD, of Cedars Sinai.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
AUA to Focus on Inclusive Care, Robotic Surgeries, and Future of Urology at 2024 Annual Meeting
May 1st 2024The American Urological Association (AUA) 2024 Annual Meeting will highlight the latest innovations and future trends in urology, featuring dynamic plenary sessions, educational opportunities for providers, and discussions on cutting-edge treatments and global health initiatives.
Read More